Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 36, 2023 - Issue 2
129
Views
0
CrossRef citations to date
0
Altmetric
Original Research: Gastroenterology

Medical and social determinants of health as predictors of adverse outcomes in patients with inflammatory bowel disease

, MD, MSORCID Icon, , MD, , MD, , MD, , PhD & , MD, PhD
Pages 165-170 | Received 22 Sep 2022, Accepted 18 Nov 2022, Published online: 21 Dec 2022

  • Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi:10.1016/S0140-6736(16)32126-2.
  • Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996–1006. doi:10.1053/j.gastro.2013.07.041.
  • Torres J, Mehandru S, Colombel J-F, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080). doi:10.1016/s0140-6736(16)31711-1.
  • Cosnes J, Bourrier A, Nion-Larmurier I, Sokol H, Beaugerie L, Seksik P. Factors affecting outcomes in Crohn’s disease over 15 years. Gut. 2012;61(8):1140–1145. doi:10.1136/gutjnl-2011-301971.
  • Reinisch W, Reinink AR, Higgins PDR. Factors associated with poor outcomes in adults with newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(4):635–642. doi:10.1016/j.cgh.2014.03.037.
  • Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis. 2012;30(Suppl 3):67–72. doi:10.1159/000342608.
  • Lamb CA, Kennedy NA, Raine T, et al; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106. doi:10.1136/gutjnl-2019-318484.
  • Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. Annual burden and costs of hospitalization for high-need, high-cost patients with chronic gastrointestinal and liver diseases. Clin Gastroenterol Hepatol. 2018;16:1284–1292. doi:10.1016/j.cgh.2018.02.015.
  • Fiscella K, Franks P, Gold MR, Clancy CM. Inequality in quality: Addressing socioeconomic, racial, and ethnic disparities in health care. JAMA. 2000;283(19):2579–2584. doi:10.1001/jama.283.19.2579.
  • Fraze TK, Brewster AL, Lewis VA, Beidler LB, Murray GF, Colla CH. Prevalence of screening for food insecurity, housing instability, utility needs, transportation needs, and interpersonal violence by US physician practices and hospitals. JAMA Netw Open. 2019;2(9):e1911514. doi:10.1001/jamanetworkopen.2019.11514.
  • Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. Estimates of the prevalence and effects of food insecurity and social support on financial toxicity in and healthcare use by patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2021;19(7):1377–1386.e5. doi:10.1016/j.cgh.2020.05.056.
  • Bernstein CN, Walld R, Marrie RA. Social determinants of outcomes in inflammatory bowel disease. Am J Gastroenterol. 2020;115(12):2036–2046. doi:10.14309/ajg.0000000000000794.
  • Siegel CA, Bernstein CN. Identifying patients with inflammatory bowel diseases at high vs low risk of complications. Clin Gastroenterol Hepatol. 2020;18(6):1261–1267. doi:10.1016/j.cgh.2019.11.034.
  • Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018;(4). doi:10.1002/14651858.cd000542.pub3.
  • Lewis JD, Chen EZ, Baldassano RN, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn’s disease. Cell Host Microbe. 2015;18(4):489–500. doi:10.1016/j.chom.2015.09.008.
  • Levine A, Rhodes JM, Lindsay JO, et al. Dietary guidance from the International Organization for the Study of Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020;18(6):1381–1392. doi:10.1016/j.cgh.2020.01.046.
  • Brotherton CS, Martin CA, Long MD, Kappelman MD, Sandler RS. Avoidance of fiber is associated with greater risk of Crohn’s disease flare in a 6-month period. Clin Gastroenterol Hepatol. 2016;14(8):1130–1136. doi:10.1016/j.cgh.2015.12.029.
  • Axelrad JE, Sharma R, Laszkowska M, Packey C, Rosenberg R, Lebwohl B. Increased healthcare utilization by patients with inflammatory bowel disease covered by Medicaid at a tertiary care center. Inflamm Bowel Dis. 2019;25(10):1711–1717. doi:10.1093/ibd/izz060.
  • Wolfe MK, McDonald NC, Holmes GM. Transportation barriers to health care in the United States: findings from the National Health Interview Survey, 1997–2017. Am J Public Health. 2020;110(6):815–822. doi:10.2105/AJPH.2020.305579.
  • Silver D, Blustein J, Weitzman BC. Transportation to clinic: findings from a pilot clinic-based survey of low-income suburbanites. J Immigr Minor Health. 2012;14(2):350–355. doi:10.1007/s10903-010-9410-0.
  • Arcury TA, Preisser JS, Gesler WM, Powers JM. Access to transportation and health care utilization in a rural region. J Rural Health. 2005;21(1):31–38. doi:10.1111/j.1748-0361.2005.tb00059.x.
  • Mikocka-Walus A, Knowles SR, Keefer L, Graff L. Controversies revisited. Inflamm Bowel Dis. 2016;22(3):752–762. doi:10.1097/MIB.0000000000000620.
  • Mikocka-Walus A, Pittet V, Rossel J-B, et al; Swiss IBD Cohort Study Group. Symptoms of depression and anxiety are independently associated with clinical recurrence of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(6):829–835.e1. doi:10.1016/j.cgh.2015.12.045.
  • Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med. 2004;66(1):79–84. doi:10.1097/01.psy.0000106907.24881.f2.
  • Langhorst J, Hofstetter A, Wolfe F, Häuser W. Short-term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis. Inflamm Bowel Dis. 2013;19(11):2380–2386. doi:10.1097/MIB.0b013e3182a192ba.
  • Persoons P, Vermeire S, Demyttenaere K, et al. The impact of major depressive disorder on the short‐ and long‐term outcome of Crohn’s disease treatment with infliximab. Aliment Pharmacol Ther. 2005;22(2):101–110. doi:10.1111/j.1365-2036.2005.02535.x.
  • Shale MJ, Riley SA. Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18(2):191–198. doi:10.1046/j.1365-2036.2003.01648.x.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.